Clinical research

One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES)

EuroIntervention 2005;1:165-172 - DOI10.4244/EIJV1I2A27.

Jiro Aoki
Jiro Aoki1, MD; Andrew T.L. Ong1, MBBS, FRACP; Alexandre Abizaid2, MD; Peter den Heijer3, MD, PhD; Hans Bonnier4, MD, PhD; Dougal R. McClean5, MD; Stefan Verheye6, MD, PhD; Jorge Belardi7, MD; Jose A. Condado8, MD; Michel Pieper9, MD; J. Eduardo Sousa2, MD; Marco Bressers10, MSc; Janette Symons10; Frank Litvack11, MD; Georgios Sianos1, MD, PhD; Patrick W. Serruys1*, MD, PhD
1. Erasmus Medical Center, Rotterdam, The Netherlands; 2. Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; 3. Amphia Ziekenhuis, Breda, The Netherlands; 4. Catharina Ziekenhuis, Eindhoven, The Netherlands; 5. Christchurch Hospital, Christchurc

Aims: The one year clinical benefit of various doses and release durations of paclitaxel eluted from an erodable polymer has not been evaluated so far.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

stentpaclitaxelelution release kinetics
Read next article
Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study

Latest news